Cargando…
Double Glomerulonephritis in a Patient with Ankylosing Spondylitis Treated with Biologic Agent: Extrarticolar Involvement or Anti-Tumor Necrosis Factor Alpha Injury? A Case-Based Review
With the widespreading use of biologic drugs, reports of renal injury are increasing, most of which belong to the spectrum of secondary autoimmune syndromes. We present the case of a young man affected by Ankylosing Spondylitis, treated with tumor necrosis factor alpha inhibitors (Anti-TNF) that dev...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683916/ https://www.ncbi.nlm.nih.gov/pubmed/33281463 http://dx.doi.org/10.1177/1179547620974672 |
_version_ | 1783612978825789440 |
---|---|
author | Diena, Davide Priora, Marta Barreca, Antonella Parisi, Simone Colla, Loredana Biancone, Luigi Fusaro, Enrico |
author_facet | Diena, Davide Priora, Marta Barreca, Antonella Parisi, Simone Colla, Loredana Biancone, Luigi Fusaro, Enrico |
author_sort | Diena, Davide |
collection | PubMed |
description | With the widespreading use of biologic drugs, reports of renal injury are increasing, most of which belong to the spectrum of secondary autoimmune syndromes. We present the case of a young man affected by Ankylosing Spondylitis, treated with tumor necrosis factor alpha inhibitors (Anti-TNF) that develop a peculiar renal damage: a coexistence of 2 glomerulonephritis due to different noxae, an IgA nephropaty with a Membranous nephropathy. The first one probably related to the rheumatologic disease, the second one related to Anti-TNF. Despite the underlying mechanisms, the renal involvement both related to Ankylosing Spondylitis and secondary to biologic treatment are currently rare and not predictable. Regular control of renal function and urinalysis during treatment with anti-TNF is mandatory. A concomitant treatment with Disease Modifying Anti Rheumatic Drugs or eventually a low dose of steroids may prevent the formation of anti-drug antibodies and could limit the renal damage related to this phenomenon. |
format | Online Article Text |
id | pubmed-7683916 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-76839162020-12-03 Double Glomerulonephritis in a Patient with Ankylosing Spondylitis Treated with Biologic Agent: Extrarticolar Involvement or Anti-Tumor Necrosis Factor Alpha Injury? A Case-Based Review Diena, Davide Priora, Marta Barreca, Antonella Parisi, Simone Colla, Loredana Biancone, Luigi Fusaro, Enrico Clin Med Insights Case Rep Case Report With the widespreading use of biologic drugs, reports of renal injury are increasing, most of which belong to the spectrum of secondary autoimmune syndromes. We present the case of a young man affected by Ankylosing Spondylitis, treated with tumor necrosis factor alpha inhibitors (Anti-TNF) that develop a peculiar renal damage: a coexistence of 2 glomerulonephritis due to different noxae, an IgA nephropaty with a Membranous nephropathy. The first one probably related to the rheumatologic disease, the second one related to Anti-TNF. Despite the underlying mechanisms, the renal involvement both related to Ankylosing Spondylitis and secondary to biologic treatment are currently rare and not predictable. Regular control of renal function and urinalysis during treatment with anti-TNF is mandatory. A concomitant treatment with Disease Modifying Anti Rheumatic Drugs or eventually a low dose of steroids may prevent the formation of anti-drug antibodies and could limit the renal damage related to this phenomenon. SAGE Publications 2020-11-20 /pmc/articles/PMC7683916/ /pubmed/33281463 http://dx.doi.org/10.1177/1179547620974672 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Diena, Davide Priora, Marta Barreca, Antonella Parisi, Simone Colla, Loredana Biancone, Luigi Fusaro, Enrico Double Glomerulonephritis in a Patient with Ankylosing Spondylitis Treated with Biologic Agent: Extrarticolar Involvement or Anti-Tumor Necrosis Factor Alpha Injury? A Case-Based Review |
title | Double Glomerulonephritis in a Patient with Ankylosing Spondylitis Treated with Biologic Agent: Extrarticolar Involvement or Anti-Tumor Necrosis Factor Alpha Injury? A Case-Based Review |
title_full | Double Glomerulonephritis in a Patient with Ankylosing Spondylitis Treated with Biologic Agent: Extrarticolar Involvement or Anti-Tumor Necrosis Factor Alpha Injury? A Case-Based Review |
title_fullStr | Double Glomerulonephritis in a Patient with Ankylosing Spondylitis Treated with Biologic Agent: Extrarticolar Involvement or Anti-Tumor Necrosis Factor Alpha Injury? A Case-Based Review |
title_full_unstemmed | Double Glomerulonephritis in a Patient with Ankylosing Spondylitis Treated with Biologic Agent: Extrarticolar Involvement or Anti-Tumor Necrosis Factor Alpha Injury? A Case-Based Review |
title_short | Double Glomerulonephritis in a Patient with Ankylosing Spondylitis Treated with Biologic Agent: Extrarticolar Involvement or Anti-Tumor Necrosis Factor Alpha Injury? A Case-Based Review |
title_sort | double glomerulonephritis in a patient with ankylosing spondylitis treated with biologic agent: extrarticolar involvement or anti-tumor necrosis factor alpha injury? a case-based review |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683916/ https://www.ncbi.nlm.nih.gov/pubmed/33281463 http://dx.doi.org/10.1177/1179547620974672 |
work_keys_str_mv | AT dienadavide doubleglomerulonephritisinapatientwithankylosingspondylitistreatedwithbiologicagentextrarticolarinvolvementorantitumornecrosisfactoralphainjuryacasebasedreview AT prioramarta doubleglomerulonephritisinapatientwithankylosingspondylitistreatedwithbiologicagentextrarticolarinvolvementorantitumornecrosisfactoralphainjuryacasebasedreview AT barrecaantonella doubleglomerulonephritisinapatientwithankylosingspondylitistreatedwithbiologicagentextrarticolarinvolvementorantitumornecrosisfactoralphainjuryacasebasedreview AT parisisimone doubleglomerulonephritisinapatientwithankylosingspondylitistreatedwithbiologicagentextrarticolarinvolvementorantitumornecrosisfactoralphainjuryacasebasedreview AT collaloredana doubleglomerulonephritisinapatientwithankylosingspondylitistreatedwithbiologicagentextrarticolarinvolvementorantitumornecrosisfactoralphainjuryacasebasedreview AT bianconeluigi doubleglomerulonephritisinapatientwithankylosingspondylitistreatedwithbiologicagentextrarticolarinvolvementorantitumornecrosisfactoralphainjuryacasebasedreview AT fusaroenrico doubleglomerulonephritisinapatientwithankylosingspondylitistreatedwithbiologicagentextrarticolarinvolvementorantitumornecrosisfactoralphainjuryacasebasedreview |